- Home
- CAAP vs XENE Comparison
CAAP vs XENE Comparison
Compare CAAP & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAAP
- XENE
- Stock Information
- Founded
- CAAP 1998
- XENE 1996
- Country
- CAAP Luxembourg
- XENE Canada
- Employees
- CAAP N/A
- XENE N/A
- Industry
- CAAP Aerospace
- XENE Biotechnology: Pharmaceutical Preparations
- Sector
- CAAP Consumer Discretionary
- XENE Health Care
- Exchange
- CAAP Nasdaq
- XENE Nasdaq
- Market Cap
- CAAP 3.0B
- XENE 3.3B
- IPO Year
- CAAP 2018
- XENE 2014
- Fundamental
- Price
- CAAP $19.79
- XENE $38.98
- Analyst Decision
- CAAP Strong Buy
- XENE Strong Buy
- Analyst Count
- CAAP 1
- XENE 7
- Target Price
- CAAP $21.50
- XENE $56.00
- AVG Volume (30 Days)
- CAAP 140.3K
- XENE 408.6K
- Earning Date
- CAAP 11-20-2024
- XENE 02-27-2025
- Dividend Yield
- CAAP N/A
- XENE N/A
- EPS Growth
- CAAP 115.99
- XENE N/A
- EPS
- CAAP 2.09
- XENE N/A
- Revenue
- CAAP $1,496,122,000.00
- XENE N/A
- Revenue This Year
- CAAP $19.21
- XENE N/A
- Revenue Next Year
- CAAP $14.26
- XENE $1,600.08
- P/E Ratio
- CAAP $8.78
- XENE N/A
- Revenue Growth
- CAAP N/A
- XENE N/A
- 52 Week Low
- CAAP $13.74
- XENE $35.53
- 52 Week High
- CAAP $20.79
- XENE $50.99
- Technical
- Relative Strength Index (RSI)
- CAAP 56.22
- XENE 45.72
- Support Level
- CAAP $18.31
- XENE $38.43
- Resistance Level
- CAAP $19.98
- XENE $40.04
- Average True Range (ATR)
- CAAP 0.69
- XENE 1.40
- MACD
- CAAP 0.05
- XENE 0.02
- Stochastic Oscillator
- CAAP 86.58
- XENE 39.40
About CAAP Corporacion America Airports SA
Corporacion America Airports SA acquires, develops and operates airport concessions. Its operating segments are geographically divided into Argentina, Italy, Brazil, Uruguay, Ecuador and Armenia. The company generates a majority of its revenue from the Argentina segment. The firm's revenue is categorized into Aeronautical Revenue, Non-Aeronautical Revenue, Commercial Revenue, Construction Service Revenue, and Other Revenue.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.